TSHA-102

GENETIC3 trials

Sponsors

Taysha Gene Therapies, Inc.

Conditions

Rett Syndrome

Phase 1

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

Active, not recruitingNCT06152237

Taysha Gene Therapies, Inc.Rett Syndrome

Start: 2023-12-12End: 2031-11-02Updated: 2025-10-15

Phase 3

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

Active, not recruitingNCT05606614

Taysha Gene Therapies, Inc.Rett Syndrome

Start: 2023-03-06End: 2031-06-01Updated: 2026-07-07

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

Active, not recruitingNCT07480564

Taysha Gene Therapies, Inc.Rett Syndrome

Start: 2026-05-08End: 2031-06-01Updated: 2026-08-19

Related Papers

Preclinical Milestones in MECP2 Gene Transfer for Treating Rett Syndrome.

2024-05-091 citations

The Efficacy of a Human-Ready miniMECP2 Gene Therapy in a Pre-Clinical Model of Rett Syndrome

Genes2023-12-2418 citations